Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Common Equity (2020 - 2025)

Terns Pharmaceuticals filings provide 6 years of Common Equity readings, the most recent being $1.0 billion for Q4 2025.

  • Quarterly Common Equity rose 191.01% to $1.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 billion through Dec 2025, up 191.01% year-over-year, with the annual reading at $1.0 billion for FY2025, 191.01% up from the prior year.
  • Common Equity hit $1.0 billion in Q4 2025 for Terns Pharmaceuticals, up from $284.1 million in the prior quarter.
  • Across five years, Common Equity topped out at $1.0 billion in Q4 2025 and bottomed at $137.2 million in Q2 2022.
  • Average Common Equity over 5 years is $280.7 million, with a median of $256.9 million recorded in 2023.
  • The largest annual shift saw Common Equity skyrocketed 290.51% in 2021 before it dropped 24.33% in 2022.
  • Terns Pharmaceuticals' Common Equity stood at $160.3 million in 2021, then skyrocketed by 72.76% to $276.9 million in 2022, then fell by 7.79% to $255.4 million in 2023, then skyrocketed by 35.44% to $345.9 million in 2024, then surged by 191.01% to $1.0 billion in 2025.
  • Per Business Quant, the three most recent readings for TERN's Common Equity are $1.0 billion (Q4 2025), $284.1 million (Q3 2025), and $305.2 million (Q2 2025).